<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>XYZAL - levocetirizine dihydrochloride tablet </strong><br><strong>XYZAL - levocetirizine dihydrochloride solution </strong><br>Physicians Total Care, Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use XYZAL safely and effectively.  See full prescribing information for XYZAL.
XYZAL (levocetirizine dihydrochloride)
5 mg tablets
2.5 mg/5 mL (0.5 mg/mL) oral solution
Initial U.S. Approval: 1995 </div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div>
<a name="ifdb96b49-299e-4bbf-8fff-c3538159c27e"></a><table width="70%"><tbody class="Headless">
<tr>
<td>Indications and Usage, <span class="product-label-link" type="condition" conceptid="4280726" conceptname="Seasonal allergic rhinitis">Seasonal Allergic Rhinitis</span> (<a href="#S1.1">1.1</a>)</td>
<td>08/2009</td>
</tr>
<tr>
<td>Indications and Usage, <span class="product-label-link" type="condition" conceptid="40486433" conceptname="Perennial allergic rhinitis">Perennial Allergic Rhinitis</span> (<a href="#S1.2">1.2</a>)</td>
<td>08/2009</td>
</tr>
<tr>
<td>Indications and Usage, Chronic <span class="product-label-link" type="condition" conceptid="140803" conceptname="Idiopathic urticaria">Idiopathic Urticaria</span> (<a href="#S1.3">1.3</a>)</td>
<td>08/2009</td>
</tr>
<tr>
<td>Dosage and Administration, Children 6 months to 5 Years (<a href="#S2.3">2.3</a>)</td>
<td>08/2009</td>
</tr>
</tbody></table>
</div>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">XYZAL is a histamine H<span class="Sub">1</span>‑receptor 
antagonist indicated for: </p>
<ul>
<li>The relief of symptoms associated with seasonal and perennial allergic 
<span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span> (<a href="#S1.1">1.1</a>, <a href="#S1.2">1.2</a>)</li>
<li>The treatment of the uncomplicated skin manifestations of chronic idiopathic 
<span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span> (<a href="#S1.3">1.3</a>)</li>
</ul>
</div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul>
<li>Adults and children 12 years of age and older: 5 mg once daily in the 
evening (<a href="#S2.1">2.1</a>)</li>
<li>Children 6 to 11 years of age: 2.5 mg once daily in the evening (<a href="#S2.2">2.2</a>)</li>
<li>Children 6 months to 5 years of age: 1.25 mg (1/2 teaspoon oral solution) 
[2.5mL] once daily in the evening (<a href="#S2.3">2.3</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span> Adjust the dose in patients 12 years of age and older with 
decreased renal function (<a href="#S2.4">2.4</a>, <a href="#S12.3">12.3</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><ul>
<li>Immediate release breakable (scored) tablets, 5 mg (<a href="#S3">3</a>)</li>
<li>Immediate release oral solution, 2.5 mg per 5 mL (0.5 mg per mL) (<a href="#S3">3</a>)</li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul>
<li>Patients with a known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to levocetirizine or any of the 
ingredients of XYZAL or to cetirizine (<a href="#S4">4</a>)</li>
<li>Patients with end-stage <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> at less than 10 mL/min creatinine 
clearance or patients undergoing hemodialysis (<a href="#S4">4</a>)</li>
<li>Children 6 months to 11 years of age with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (<a href="#S4">4</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul>
<li>Avoid engaging in hazardous occupations requiring complete mental alertness 
such as driving or operating machinery when taking XYZAL (<a href="#S5.1">5.1</a>).</li>
<li>Avoid concurrent use of alcohol or other central nervous system depressants 
with XYZAL (<a href="#S5.1">5.1</a>).</li>
</ul></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">The most common adverse reactions (rate ≥2% and &gt; placebo) 
were <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">nasopharyngitis</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, and <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span> in 
subjects 12 years of age and older, and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, and 
<span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">epistaxis</span> in children 6 to 12 years of age. In subjects 1 to 5 years of age, the 
most common adverse reactions (rate ≥2% and &gt; placebo) were <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span>, 
<span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">otitis media</span>. In subjects 6 to 11 months of age, the 
most common adverse reactions (rate ≥3% and &gt; placebo) were <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> and 
<span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>. (<a href="#S6.1">6.1</a>). </p>
<br><p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact UCB, Inc. at 
866-822-0068 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</span> </p>
<br>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><p class="Highlighta">Enter highlights text here  (<a href="#section-7">7</a>)</p></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul>
<li><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span><br>Because XYZAL is substantially excreted by the kidneys, 
the risk of adverse reactions to this drug may be greater in patients with 
<span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> (<a href="#S8.6">8.6</a> and <a href="#S12.3">12.3</a>).</li>
<li>Pediatric Use<br>Do not exceed the recommended doses of 2.5 mg and 1.25 mg 
once daily in children 6 to 11 years and 6 months to 5 years of age, 
respectively. Systemic exposure with these doses in respective pediatric age 
groups is comparable to that from a 5 mg once daily dose in adults. (<a href="#S12.3">12.3</a>).</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 5/2010</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1  INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-1.1" class="toc">1.1 <span class="product-label-link" type="condition" conceptid="4280726" conceptname="Seasonal allergic rhinitis">Seasonal Allergic Rhinitis</span></a></h2>
<h2><a href="#section-1.2" class="toc">1.2 <span class="product-label-link" type="condition" conceptid="40486433" conceptname="Perennial allergic rhinitis">Perennial Allergic Rhinitis</span></a></h2>
<h2><a href="#section-1.3" class="toc">1.3 Chronic <span class="product-label-link" type="condition" conceptid="140803" conceptname="Idiopathic urticaria">Idiopathic Urticaria</span></a></h2>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Adults and Children 12 Years of Age and Older</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Children 6 to 11 Years of Age</a></h2>
<h2><a href="#section-2.3" class="toc">2.3 Children 6 months to 5 Years of A</a></h2>
<h2><a href="#section-2.4" class="toc">2.4 Dose Adjustment for Renal and <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h2><a href="#section-4.1" class="toc">4.1 Patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span></a></h2>
<h2><a href="#section-4.2" class="toc">4.2 Patients with end-stage <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span></a></h2>
<h2><a href="#section-4.3" class="toc">4.3 Pediatric patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span></a></h2>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 Activities Requiring Mental Alertness</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Post-Marketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 Antipyrine, Azithromycin, Cimetidine, Erythromycin, Ketoconazole, Theophylline, and Pseudoephedrine</a></h2>
<h2><a href="#section-7.2" class="toc">7.2 Ritonavir</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h2><a href="#section-8.6" class="toc">8.7 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h2><a href="#section-12.2" class="toc">13.2 Animal Toxicology</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-13.1" class="toc">14.1 Seasonal and <span class="product-label-link" type="condition" conceptid="40486433" conceptname="Perennial allergic rhinitis">Perennial Allergic Rhinitis</span></a></h2>
<h2><a href="#section-13.2" class="toc">14.2 Chronic <span class="product-label-link" type="condition" conceptid="140803" conceptname="Idiopathic urticaria">Idiopathic Urticaria</span></a></h2>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<h2><a href="#section-15.1" class="toc">17.1 Activities Requiring Mental Alertness</a></h2>
<h2><a href="#section-15.2" class="toc">17.2 Concomitant Use of Alcohol and other Central Nervous System Depressants</a></h2>
<h2><a href="#section-15.3" class="toc">17.3 Dosing of XYZAL</a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="S1"></a><a name="section-1"></a><p></p>
<h1>1  INDICATIONS AND USAGE</h1>
<p class="First">Enter section text here</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1.1"></a><p></p>
<h2>1.1 <span class="product-label-link" type="condition" conceptid="4280726" conceptname="Seasonal allergic rhinitis">Seasonal Allergic Rhinitis</span></h2>
<p class="First"><span>XYZAL<span class="Sup">®</span> is indicated for the relief of symptoms associated with 
<span class="product-label-link" type="condition" conceptid="4280726" conceptname="Seasonal allergic rhinitis">seasonal allergic rhinitis</span> in adults and children 2 years of age and 
older.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1.2"></a><p></p>
<h2>1.2 <span class="product-label-link" type="condition" conceptid="40486433" conceptname="Perennial allergic rhinitis">Perennial Allergic Rhinitis</span></h2>
<p class="First"><span>XYZAL 
is indicated for the relief of symptoms associated with perennial allergic 
<span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span> in adults and children 6 months of age and older.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1.3"></a><p></p>
<h2>1.3 Chronic <span class="product-label-link" type="condition" conceptid="140803" conceptname="Idiopathic urticaria">Idiopathic Urticaria</span></h2>
<p class="First"><span>XYZAL 
is indicated for the treatment of the uncomplicated skin manifestations of 
chronic <span class="product-label-link" type="condition" conceptid="140803" conceptname="Idiopathic urticaria">idiopathic urticaria</span> in adults and children 6 months of age and 
older.</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="S2"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<p class="First">XYZAL is available as 2.5 mg/5 mL (0.5 mg/mL) oral solution and as 5 mg 
breakable (scored) tablets, allowing for the administration of 2.5 mg, if 
needed. XYZAL can be taken without regard to food consumption. </p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.1"></a><p></p>
<h2>2.1 Adults and Children 12 Years of Age and Older</h2>
<p class="First">The recommended dose of XYZAL is 5 mg (1 tablet or 2 teaspoons [10 mL] oral 
solution) once daily in the evening. Some patients may be adequately controlled 
by 2.5 mg (1/2 tablet or 1 teaspoon [5 mL] oral solution) once daily in the 
evening.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.2"></a><p></p>
<h2>2.2 Children 6 to 11 Years of Age</h2>
<p class="First">The recommended dose of XYZAL is 2.5 mg (1/2 tablet or 1 teaspoon [5 mL] oral 
solution) once daily in the evening. The 2.5 mg dose should not be exceeded 
because the systemic exposure with 5 mg is approximately twice that of adults 
[see <span class="Italics"><a href="#S12.3">Clinical Pharmacology 
(12.3)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.3"></a><p></p>
<h2>2.3 Children 6 months to 5 Years of A</h2>
<p class="First"><span>The 
recommended initial dose of XYZAL is 1.25 mg (1/2 teaspoon oral solution) 
[2.5mL] once daily in the evening. The 1.25 mg once daily dose should not be 
exceeded based on comparable exposure to adults receiving 5 mg [see <span class="Italics"><a href="#S12.3">Clinical Pharmacology (12.3)</a></span>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.4"></a><p></p>
<h2>2.4 Dose Adjustment for Renal and <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">In adults and children 12 years of age and older with: </p>
<ul>
<li>Mild <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (creatinine clearance [CL<span class="Sub">CR</span>] = 
50-80 mL/min): a dose of 2.5 mg once daily is recommended;</li>
<li>Moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (CL<span class="Sub">CR</span> = 30-50 mL/min): a 
dose of 2.5 mg once every other day is recommended;</li>
<li>Severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (CL<span class="Sub">CR</span> = 10-30 mL/min): a dose 
of 2.5 mg twice weekly (administered once every 3-4 days) is recommended;</li>
<li>End-stage <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> patients (CL<span class="Sub">CR</span> less than 10 
mL/min) and patients undergoing hemodialysis should not receive XYZAL.</li>
</ul>
<p>No dose adjustment is needed in patients with solely <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. In 
patients with both <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> and <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, adjustment of the 
dose is recommended.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="S3"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">XYZAL oral solution is a clear, colorless liquid containing 0.5 
mg of levocetirizine dihydrochloride per mL.</p>
<p>XYZAL tablets are white, film‑coated, oval-shaped, scored, imprinted (with 
the letter Y in red color on both halves of the scored tablet) and contain 5 mg 
levocetirizine dihydrochloride.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="S4"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">The use of XYZAL is contraindicated in:</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.1"></a><p></p>
<h2>4.1 Patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span></h2>
<p class="First">Patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to levocetirizine or any of the ingredients 
of XYZAL, or to cetirizine. Observed reactions range from <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span> to 
<span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> [see <span class="Italics"><a href="#S6.2">Adverse Reactions 
(6.2)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.2"></a><p></p>
<h2>4.2 Patients with end-stage <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span></h2>
<p class="First">Patients with end-stage <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> (CL<span class="Sub">CR</span> less than 10 
mL/min) and patients undergoing hemodialysis</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.3"></a><p></p>
<h2>4.3 Pediatric patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span></h2>
<p class="First">Children 6 months to 11 years of age with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> </p>
</div>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="S5"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<p class="First">Enter section text here</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.1"></a><p></p>
<h2>5.1 Activities Requiring Mental Alertness</h2>
<p class="First">In clinical trials the occurrence of <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, and <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span> has been 
reported in some patients under therapy with XYZAL. Patients should be cautioned 
against engaging in hazardous occupations requiring complete mental alertness, 
and motor coordination such as operating machinery or driving a motor vehicle 
after ingestion of XYZAL. Concurrent use of XYZAL with alcohol or other central 
nervous system depressants should be avoided because additional reductions in 
alertness and additional impairment of central nervous system performance may 
occur.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="S6"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">Use of XYZAL has been associated with <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, and <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span> 
[see<span class="Italics"><a href="#S5.1">Warnings and Precautions 
(5.1)</a></span>].</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience</h2>
<p class="First">    <br></p>
<p>The safety data described below reflect exposure to XYZAL in 2708 
patients with seasonal or <span class="product-label-link" type="condition" conceptid="40486433" conceptname="Perennial allergic rhinitis">perennial allergic rhinitis</span> or chronic idiopathic 
<span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span> in 14 controlled clinical trials of 1 week to 6 months duration.</p>
<p>The short-term (exposure up to 6 weeks) safety data for adults and 
adolescents are based upon eight clinical trials in which 1896 patients (825 
males and 1071 females aged 12 years and older) were treated with XYZAL 2.5, 5, 
or 10 mg once daily in the evening.</p>
<p>The short-term safety data from pediatric patients are based upon two 
clinical trials in which 243 children with seasonal or perennial allergic 
<span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span> (162 males and 81 females 6 to 12 years of age) were treated with XYZAL 
5 mg once daily for 4 to 6 weeks, one clinical trial in which 114 children (65 
males and 49 females 1 to 5 years of age) with <span class="product-label-link" type="condition" conceptid="257007" conceptname="Allergic rhinitis">allergic rhinitis</span> or chronic 
<span class="product-label-link" type="condition" conceptid="140803" conceptname="Idiopathic urticaria">idiopathic urticaria</span> were treated with XYZAL 1.25 mg twice daily for 2 weeks, 
and one clinical trial in which 45 children (28 males and 17 females 6 to 11 
months of age) with symptoms of <span class="product-label-link" type="condition" conceptid="257007" conceptname="Allergic rhinitis">allergic rhinitis</span> or <span class="product-label-link" type="condition" conceptid="4198855" conceptname="Chronic urticaria">chronic urticaria</span> were 
treated with XYZAL 1.25 mg once daily for 2 weeks.</p>
<p>The long-term (exposure of 4 or 6 months) safety data in adults and 
adolescents are based upon two clinical trials in which 428 patients (190 males 
and 238 females) with <span class="product-label-link" type="condition" conceptid="257007" conceptname="Allergic rhinitis">allergic rhinitis</span> were exposed to treatment with XYZAL 5 
mg once daily. Long term safety data are also available from an 18-month trial 
in 255 XYZAL-treated subjects 12-24 months of age.</p>
<p>Because clinical trials are conducted under widely varying conditions, 
adverse reaction rates observed in the clinical trials of a drug cannot be 
directly compared to rates in the clinical trial of another drug and may not 
reflect the rates observed in practice.</p>
<a href="http://"></a><a href="http://"></a><p><span>Adults and Adolescents 12 years of Age 
and Older</span></p>
<p>In studies up to 6 weeks in duration, the mean age of the adult and 
adolescent patients was 32 years, 44% of the patients were men and 56% were 
women, and the large majority (more than 90%) was Caucasian.</p>
<p>In these trials 43% and 42% of the subjects in the XYZAL 2.5 mg and 5 mg 
groups, respectively, had at least one adverse event compared to 43% in the 
placebo group.</p>
<p>In placebo-controlled trials of 1-6 weeks in duration, the most common 
adverse reactions were <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">nasopharyngitis</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, and 
<span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span>, and most were mild to moderate in intensity. <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span> with XYZAL 
showed dose ordering between tested doses of 2.5, 5 and 10 mg and was the most 
common adverse reaction leading to discontinuation (0.5%).</p>
<p>Table 1 lists adverse reactions that were reported in greater than or equal 
to 2% of subjects aged 12 years and older exposed to XYZAL 2.5 mg or 5 mg in 
eight placebo-controlled clinical trials and that were more common with XYZAL 
than placebo.</p>
<a name="id8efa730-0b7c-4cd4-88ba-2e8e5ed0aed6"></a><table width="80%">
<caption><span>Table 1 Adverse Reactions Reported in ≥ 2%* of Subjects Aged 12 Years and Older Exposed to XYZAL 2.5 mg or 5 mg Once Daily in Placebo-Controlled Clinical Trials 1-6 Weeks in Duration</span></caption>
<tbody class="Headless">
<tr class="First">
<td><span class="Bold">Adverse Reactions</span></td>
<td><span class="Bold">XYZAL 2.5 mg<br>(n = 421)</span></td>
<td><span class="Bold">XYZAL 5 mg<br>(n = 1070)</span></td>
<td><span class="Bold">Placebo<br>(n = 912)<br></span></td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span><br>
</td>
<td>22 (5%)<br>
</td>
<td>61 (6%)<br>
</td>
<td>16 (2%)<br>
</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">Nasopharyngitis</span><br>
</td>
<td>25 (6%)<br>
</td>
<td>40 (4%)<br>
</td>
<td>28 (3%)<br>
</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span><br>
</td>
<td>5 (1%)<br>
</td>
<td>46 (4%)<br>
</td>
<td>20 (2%)<br>
</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">Dry Mouth</span><br>
</td>
<td>12 (3%)<br>
</td>
<td>26 (2%)<br>
</td>
<td>11 (1%)<br>
</td>
</tr>
<tr class="Last">
<td><span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">Pharyngitis</span><br>
</td>
<td>10 (2%)<br>
</td>
<td>12 (1%)<br>
</td>
<td>9 (1%)<br>
</td>
</tr>
</tbody>
</table>*   Rounded to the closest unit percentage<br><br><p>Additional adverse reactions of medical significance observed at a higher 
incidence than in placebo in adults and adolescents aged 12 years and older 
exposed to XYZAL are <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span> (0.2%) and <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight increased</span> (0.5%).</p>
<a href="http://"></a><a href="http://"></a><p><span>Pediatric Patients 6 to 12 Years of 
Age</span></p>
<p>A total of 243 pediatric patients 6 to 12 years of age received XYZAL 5 mg 
once daily in two short-term placebo controlled double-blind trials. The mean 
age of the patients was 9.8 years, 79 (32%) were 6 to 8 years of age, and 50% 
were Caucasian. Table 2 lists adverse reactions that were reported in greater 
than or equal to 2% of subjects aged 6 to 12 years exposed to XYZAL 5 mg in 
placebo-controlled clinical trials and that were more common with XYZAL than 
placebo. </p>
<a name="i8f6d0c6c-c117-4a4f-8fa1-f77e729cdd4c"></a><table width="80%">
<caption><span>Table 2 Adverse Reactions Reported in ≥2%* of Subjects Aged 6-12 Years Exposed to XYZAL 5 mg Once Daily in Placebo-Controlled Clinical Trials 4 and 6 Weeks in Duration</span></caption>
<tbody class="Headless">
<tr class="First">
<td>
<span class="Bold">Adverse Reactions</span><br>
</td>
<td><span class="Bold">XYZAL 5 mg<br>(n = 243)<br></span></td>
<td><span class="Bold">Placebo<br>(n = 240)<br></span></td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Pyrexia</span><br>
</td>
<td>10 (4%)<br>
</td>
<td>5 (2%)<br>
</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span><br>
</td>
<td> 8 (3%)<br>
</td>
<td>2 (less than 1%)<br>
</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span><br>
</td>
<td>7 (3%)<br>
</td>
<td>1 (less than 1%)<br>
</td>
</tr>
<tr class="Last">
<td><span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">Epistaxis</span><br>
</td>
<td>6 (2%)<br>
</td>
<td>1 (less than 1%)<br>
</td>
</tr>
</tbody>
</table>*  Rounded to the closest unit percentage<br><br><p><span>Pediatric Patients 1 to 5 Years of 
Age</span></p>
<p>A total of 114 pediatric patients 1 to 5 years of age received XYZAL 1.25 mg 
twice daily in a two week placebo-controlled double-blind safety trial. The mean 
age of the patients was 3.8 years, 32% were 1 to 2 years of age, 71% were 
Caucasian and 18% were Black. Table 3 lists adverse reactions that were reported 
in greater than or equal to 2% of subjects aged 1 to 5 years exposed to XYZAL 
1.25 mg twice daily in the placebo-controlled safety trial and that were more 
common with XYZAL than placebo.</p>
<a name="ieeee6b49-96ff-450b-855c-dbcfa7565298"></a><table width="80%">
<caption><span>Table 3 Adverse Reactions Reported in ≥2%* of Subjects Aged 1-5 Years Exposed to XYZAL 1.25 mg Twice Daily in a 2-Week Placebo-Controlled Clinical Trial</span></caption>
<tbody class="Headless">
<tr class="First">
<td>
<span class="Bold">Adverse Reactions</span><br>
</td>
<td><span class="Bold">XYZAL 1.25 mg Twice Daily<br>(n = 114)<br></span></td>
<td><span class="Bold">Placebo<br>(n = 59)<br></span></td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Pyrexia</span><br>
</td>
<td>5 (4%)<br>
</td>
<td>1 (2%)<br>
</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span><br>
</td>
<td>4 (4%)<br>
</td>
<td>2 (3%)<br>
</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span><br>
</td>
<td>4 (4%)<br>
</td>
<td>2 (3%)<br>
</td>
</tr>
<tr class="Last">
<td><span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">Otitis Media</span><br>
</td>
<td>3 (3%)<br>
</td>
<td>0 (0%)<br>
</td>
</tr>
</tbody>
</table>*   Rounded to the closest unit percentage<br><br><p><span>Pediatric Patients 6 to 11 Months of 
Age</span></p>
<p>A total of 45 pediatric patients 6 to 11 months of age received XYZAL 1.25 mg 
once daily in a two week placebo-controlled double-blind safety trial. The mean 
age of the patients was 9 months, 51% were Caucasian and 31% were Black. Adverse 
reactions that were reported in more than 1 subject (i.e. greater than or equal 
to 3% of subjects) aged 6 to 11 months exposed to XYZAL 1.25 mg once daily in 
the placebo-controlled safety trial and that were more common with XYZAL than 
placebo included <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> and <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> which were reported in 6 (13%) and 1 
(4%) and 3 (7%) and 1 (4%) children in the XYZAL and placebo-treated groups, 
respectively.</p>
<a href="http://"></a><a href="http://"></a><p><span>Long-Term Clinical Trials 
Experience</span></p>
<p>In two controlled clinical trials, 428 patients (190 males and 238 females) 
aged 12 years and older were treated with XYZAL 5 mg once daily for 4 or 6 
months. The patient characteristics and the safety profile were similar to that 
seen in the short-term studies. Ten (2.3%) patients treated with XYZAL 
discontinued because of <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span> or <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span> compared to 2 (less than 1%) 
in the placebo group.</p>
<p>There are no long term clinical trials in children below 12 years of age with 
<span class="product-label-link" type="condition" conceptid="257007" conceptname="Allergic rhinitis">allergic rhinitis</span> or chronic <span class="product-label-link" type="condition" conceptid="140803" conceptname="Idiopathic urticaria">idiopathic urticaria</span>. </p>
<a href="http://"></a><a href="http://"></a><p><span>Laboratory Test Abnormalities</span></p>
<p>Elevations of blood bilirubin and transaminases were reported in less than 1% of 
patients in the clinical trials. The elevations were transient and did not lead 
to discontinuation in any patient.</p>
<br><br><br>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.2"></a><p></p>
<h2>6.2 Post-Marketing Experience</h2>
<p class="First">In addition to the adverse reactions reported during clinical 
trials and listed above, adverse events have also been identified during 
post-approval use of XYZAL in other countries. Because these events are reported 
voluntarily from a population of uncertain size, it is not always possible to 
reliably estimate their frequency or establish a causal relationship to drug 
exposure. Adverse events of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> and <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, angioneurotic 
<span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="4080559" conceptname="Baboon syndrome">fixed drug eruption</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, and <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsion</span>, 
<span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">aggression</span> and <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">visual disturbances</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, 
<span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, and <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span> have been reported. </p>
<p>Besides these events reported under treatment with XYZAL, other potentially 
severe adverse events have been reported from the post-marketing experience with 
cetirizine. Since levocetirizine is the principal pharmacologically active 
component of cetirizine, one should take into account the fact that the 
following adverse events could also potentially occur under treatment with 
XYZAL: <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, <span class="product-label-link" type="condition" conceptid="4092095" conceptname="Planning suicide">suicidal ideation</span>, <span class="product-label-link" type="condition" conceptid="376969" conceptname="Orofacial dyskinesia">orofacial dyskinesia</span>, severe 
<span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4143915" conceptname="Cholestasis">cholestasis</span>, <span class="product-label-link" type="condition" conceptid="4263367" conceptname="Glomerulonephritis">glomerulonephritis</span>, and still birth.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<p class="First"><span class="Italics">In vitro</span> data indicate that levocetirizine is 
unlikely to produce <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interactions</span> through inhibition or induction 
of liver drug-metabolizing enzymes. No <span class="Italics">in vivo</span> 
drug-drug interaction studies have been performed with levocetirizine. Drug 
interaction studies have been performed with racemic cetirizine.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.1"></a><p></p>
<h2>7.1 Antipyrine, Azithromycin, Cimetidine, Erythromycin, Ketoconazole, Theophylline, and Pseudoephedrine</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">Pharmacokinetic interaction</span> studies performed with racemic cetirizine 
demonstrated that cetirizine did not interact with antipyrine, pseudoephedrine, 
erythromycin, azithromycin, ketoconazole, and cimetidine. There was a small 
decrease (~16%) in the clearance of cetirizine caused by a 400 mg dose of 
theophylline. It is possible that higher theophylline doses could have a greater 
effect.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.2"></a><p></p>
<h2>7.2 Ritonavir</h2>
<p class="First">Ritonavir increased the plasma AUC of cetirizine by about 42% accompanied by an 
increase in half-life (53%) and a decrease in clearance (29%) of cetirizine. The 
disposition of ritonavir was not altered by concomitant cetirizine 
administration.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="S8"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<p class="First">Enter section text here</p>
<div class="Section" data-sectionCode="42228-7">
<a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First"><span class="Bold">Pregnancy Category B</span></p>
<p>There are no adequate and well-controlled studies in pregnant women. Because 
animal reproduction studies are not always predictive of human response, XYZAL 
should be used during pregnancy only if clearly needed.</p>
<a href="http://"></a><a href="http://"></a><p><span class="Bold">Teratogenic Effects:</span></p>
<p>In rats and rabbits, levocetirizine was not teratogenic at oral doses 
approximately 320 and 390, respectively, times the maximum recommended daily 
oral dose in adults on a mg/m<span class="Sup">2 </span>basis. </p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">No peri- and post-natal animal studies have been conducted with levocetirizine. 
In mice, cetirizine caused retarded pup <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> during lactation at an oral 
dose in dams that was approximately 40 times the maximum recommended daily oral 
dose in adults on a mg/m<span class="Sup">2</span> basis. Studies in beagle dogs 
indicated that approximately 3% of the dose of cetirizine was excreted in milk. 
Cetirizine has been reported to be excreted in human breast milk. Because 
levocetirizine is also expected to be excreted in human milk, use of XYZAL in 
nursing mothers is not recommended.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">The recommended dose of XYZAL for the treatment of the 
uncomplicated skin manifestations of chronic <span class="product-label-link" type="condition" conceptid="140803" conceptname="Idiopathic urticaria">idiopathic urticaria</span> in patients 6 
months to 17 years of age is based on extrapolation of efficacy from adults 18 
years of age and older [see<span class="Italics"><a href="#S14"> Clinical Studies 
(14)</a></span>].</p>
<p>The recommended dose of XYZAL in patients 6 months to 11 years of age for the 
treatment of the symptoms of <span class="product-label-link" type="condition" conceptid="40486433" conceptname="Perennial allergic rhinitis">perennial allergic rhinitis</span> and chronic idiopathic 
<span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span> and in patients 2 to 11 years of age for the treatment of the symptoms 
of <span class="product-label-link" type="condition" conceptid="4280726" conceptname="Seasonal allergic rhinitis">seasonal allergic rhinitis</span> is based on cross-study comparisons of the 
systemic exposure of XYZAL in adults and pediatric patients and on the safety 
profile of XYZAL in both adult and pediatric patients at doses equal to or 
higher than the recommended dose for patients 6 months to 11 years of age. </p>
<p>The safety of XYZAL 5 mg once daily was evaluated in 243 pediatric patients 6 
to 12 years of age in two placebo-controlled clinical trials lasting 4 and 6 
weeks. The safety of XYZAL 1.25 mg twice daily was evaluated in one 2-week 
clinical trial in 114 pediatric patients 1 to 5 years of age and the safety of 
XYZAL 1.25 mg once daily was evaluated in one 2-week clinical trial in 45 
pediatric patients 6 to 11 months of age [see <span class="Italics"><a href="#S6.1">Adverse Reactions (6.1)</a></span>].</p>
<p>The effectiveness of XYZAL 1.25 mg once daily (6 months to 5 years of age) 
and 2.5 mg once daily (6 to 11 years of age) for the treatment of the symptoms 
of seasonal and <span class="product-label-link" type="condition" conceptid="40486433" conceptname="Perennial allergic rhinitis">perennial allergic rhinitis</span> and chronic <span class="product-label-link" type="condition" conceptid="140803" conceptname="Idiopathic urticaria">idiopathic urticaria</span> is 
supported by the extrapolation of demonstrated efficacy of XYZAL 5 mg once daily 
in patients 12 years of age and older and based on the pharmacokinetic 
comparison between adults and children.</p>
<p>Cross-study comparisons indicate that administration of a 5 mg dose of XYZAL 
to 6 to 12 year old pediatric <span class="product-label-link" type="condition" conceptid="4280726" conceptname="Seasonal allergic rhinitis">seasonal allergic rhinitis</span> patients resulted in 
about 2-fold the systemic exposure (AUC) observed when 5 mg of XYZAL was 
administered to healthy adults. Therefore, in children 6 to 11 years of age the 
recommended dose of 2.5 mg once daily should not be exceeded. In a population 
pharmacokinetics study the administration of 1.25 mg once daily in children 6 
months to 5 years of age resulted in systemic exposure comparable to 5 mg once 
daily in adults. [see <span class="Italics"><a href="#S2.2">Dosage and 
Administration (2.2)</a>; <a href="#S14">Clinical Studies (14)</a>; </span>and 
<span class="Italics"><a href="#S12.3">Clinical Pharmacology (12.3)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Clinical studies of XYZAL for each approved indication did not include 
sufficient numbers of patients aged 65 years and older to determine whether they 
respond differently than younger patients. Other reported clinical experience 
has not identified differences in responses between the elderly and younger 
patients. In general, dose selection for an elderly patient should be cautious, 
usually starting at the low end of the dosing range reflecting the greater 
frequency of decreased hepatic, renal, or cardiac function and of concomitant 
disease or other drug therapy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.5"></a><p></p>
<h2>8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">XYZAL is known to be substantially excreted by the kidneys and the risk of 
adverse reactions to this drug may be greater in patients with impaired renal 
function. Because elderly patients are more likely to have decreased renal 
function, care should be taken in dose selection and it may be useful to monitor 
renal function [see <span class="Italics"><a href="#S2">Dosage and Administration 
(2)</a></span> and <span class="Italics"><a href="#S12.3">Clinical Pharmacology 
(12.3)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.6"></a><p></p>
<h2>8.7 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">As levocetirizine is mainly excreted unchanged by the kidneys, it is unlikely 
that the clearance of levocetirizine is significantly decreased in patients with 
solely <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> [see <span class="Italics"><a href="#S12.3">Clinical 
Pharmacology (12.3)</a></span>].</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">Overdosage has been reported with XYZAL.</p>
<p>Symptoms of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> may include <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> in adults and initially <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span> 
and <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>, followed by <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> in children. There is no known specific 
antidote to XYZAL. Should <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> occur, symptomatic or supportive treatment is 
recommended. XYZAL is not effectively removed by dialysis, and dialysis will be 
ineffective unless a dialyzable agent has been concomitantly ingested.</p>
<p>The acute maximal non-lethal oral dose of levocetirizine was 240 mg/kg in 
mice (approximately 190 times the maximum recommended daily oral dose in adults, 
approximately 230 times the maximum recommended daily oral dose in children 6 to 
11 years of age, and approximately 180 times the maximum recommended daily oral 
dose in children 6 months to 5 years of age on a mg/m<span class="Sup">2 
</span>basis). In rats the maximal non-lethal oral dose was 240 mg/kg 
(approximately 390 times the maximum recommended daily oral dose in adults, 
approximately 460 times the maximum recommended daily oral dose in children 6 to 
11 years of age, and approximately 370 times the maximum recommended daily oral 
dose in children 6 months to 5 years of age on a mg/m<span class="Sup">2</span> 
basis).</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">Levocetirizine dihydrochloride, the active component of XYZAL tablets and oral 
solution, is an orally active H<span class="Sub">1</span>‑receptor antagonist. The 
chemical name is (R)-[2-[4-[(4-chlorophenyl) phenylmethyl]-1-piperazinyl] 
ethoxy] acetic acid dihydrochloride. Levocetirizine dihydrochloride is the R 
enantiomer of cetirizine hydrochloride, a racemic compound with antihistaminic 
properties. The empirical formula of levocetirizine dihydrochloride is C<span class="Sub">21</span>H<span class="Sub">25</span>ClN<span class="Sub">2</span>O<span class="Sub">3</span>•2HCl. The molecular weight is 461.82 and the chemical 
structure is shown below:</p>
<div class="Figure"><img alt="image of chemical structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=371ca86d-7ffd-4f20-b6c6-af0a9ff7362f&amp;name=chemical%20structure.jpg"></div>
<p>Levocetirizine dihydrochloride is a white, crystalline powder and is water 
soluble. </p>
<p>XYZAL 5 mg tablets are formulated as immediate release, white, film-coated, 
oval-shaped scored tablets for oral administration. The tablets are imprinted on 
both halves of the scored line with the letter Y in red (Opacode<span class="Sup">®</span> Red). Inactive ingredients are: microcrystalline cellulose, 
lactose monohydrate, colloidal anhydrous silica, and magnesium stearate. The 
film coating contains hypromellose, titanium dioxide, and macrogol 400.</p>
<p>XYZAL 0.5 mg/mL oral solution is formulated as an immediate release, clear, 
colorless liquid. Inactive ingredients are: sodium acetate trihydrate, glacial 
acetic acid, maltitol solution, glycerin, methylparaben, propylparaben, 
saccharin, flavoring (consisting of triacetin, natural &amp; artificial flavors, 
dl-alpha-tocopherol), purified water.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<p class="First">Enter section text here</p>
<div class="Section" data-sectionCode="43679-0">
<a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Levocetirizine, the active enantiomer of cetirizine, is an anti-histamine; its 
principal effects are mediated via selective inhibition of H<span class="Sub">1</span> receptors. The antihistaminic activity of levocetirizine has 
been documented in a variety of animal and human models. <span class="Italics">In 
vitro</span> binding studies revealed that levocetirizine has an affinity for 
the human H<span class="Sub">1</span>-receptor 2-fold higher than that of 
cetirizine (Ki = 3 nmol/L <span class="Italics">vs.</span> 6 nmol/L, 
respectively). The clinical relevance of this finding is unknown.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="section-11.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<p class="First">Studies in adult healthy subjects showed that levocetirizine at 
doses of 2.5 mg and 5 mg inhibited the skin wheal and flare caused by the 
intradermal injection of histamine. In contrast, dextrocetirizine exhibited no 
clear change in the inhibition of the wheal and flare reaction. Levocetirizine 
at a dose of 5 mg inhibited the wheal and flare caused by intradermal injection 
of histamine in 14 pediatric subjects (aged 6 to 11 years) and the activity 
persisted for at least 24 hours. The clinical relevance of histamine wheal skin 
testing is unknown.</p>
<p>A QT/QTc study using a single dose of 30 mg of levocetirizine did not 
demonstrate an effect on the QTc interval. While a single dose of levocetirizine 
had no effect, the effects of levocetirizine may not be at steady state 
following single dose. The effect of levocetirizine on the QTc interval 
following multiple dose administration is unknown. Levocetirizine is not 
expected to have QT/QTc effects because of the results of QTc studies with 
cetirizine and the long post-marketing history of cetirizine without reports of 
QT prolongation.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="section-11.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">Levocetirizine exhibited linear pharmacokinetics over the 
therapeutic dose range in adult healthy subjects.</p>
<a href="http://"></a><a href="http://"></a><p><span class="Bold">    •    Absorption</span></p>
<p>Levocetirizine is rapidly and extensively absorbed following oral 
administration. In adults, peak plasma concentrations are achieved 0.9 hour 
after administration of the oral tablet. The accumulation ratio following daily 
oral administration is 1.12 with steady state achieved after 2 days. Peak 
concentrations are typically 270 ng/mL and 308 ng/mL following a single and a 
repeated 5 mg once daily dose, respectively. Food had no effect on the extent of 
exposure (AUC) of the levocetirizine tablet, but T<span class="Sub">max</span> was 
delayed by about 1.25 hours and C<span class="Sub">max</span> was decreased by 
about 36% after administration with a high fat meal; therefore, levocetirizine 
can be administered with or without food.</p>
<p>A dose of 5 mg (10 mL) of XYZAL oral solution is bioequivalent to a 5 mg dose 
of XYZAL tablets. Following oral administration of a 5 mg dose of XYZAL oral 
solution to healthy adult subjects, the mean peak plasma concentrations were 
achieved approximately 0.5 hour post-dose.</p>
<a href="http://"></a><a href="http://"></a><p><span class="Bold">    •    Distribution</span></p>
<p>The mean plasma protein binding of levocetirizine <span class="Italics">in 
vitro</span> ranged from 91 to 92%, independent of concentration in the range of 
90-5000 ng/mL, which includes the therapeutic plasma levels observed. Following 
oral dosing, the average apparent volume of distribution is approximately 0.4 
L/kg, representative of distribution in total body water.</p>
<a href="http://"></a><a href="http://"></a><p><span class="Bold">    •    Metabolism</span></p>
<p>The extent of metabolism of levocetirizine in humans is less than 14% of the 
dose and therefore differences resulting from genetic polymorphism or 
concomitant intake of hepatic drug metabolizing enzyme inhibitors are expected 
to be negligible. Metabolic pathways include aromatic oxidation, N- and 
O-dealkylation, and taurine conjugation. Dealkylation pathways are primarily 
mediated by CYP 3A4 while aromatic oxidation involves multiple and/or 
unidentified CYP isoforms.</p>
<a href="http://"></a><a href="http://"></a><p><span class="Bold">    •    Elimination</span></p>
<p>The plasma half-life in adult healthy subjects was about 8 to 9 hours after 
administration of oral tablets and oral solution, and the mean oral total body 
clearance for levocetirizine was approximately 0.63 mL/kg/min. The major route 
of excretion of levocetirizine and its metabolites is via urine, accounting for 
a mean of 85.4% of the dose. Excretion via feces accounts for only 12.9% of the 
dose. Levocetirizine is excreted both by glomerular filtration and active 
tubular secretion. Renal clearance of levocetirizine correlates with that of 
creatinine clearance. In patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> the clearance of 
levocetirizine is reduced [see <span class="Italics"><a href="#S2.3">Dosage and 
Administration (2.3)</a></span>].</p>
<a href="http://"></a><a href="http://"></a><p><span class="Bold">    •    Drug Interaction Studies</span></p>
<p><span class="Italics">In vitro</span> data on metabolite interaction indicate 
that levocetirizine is unlikely to produce, or be subject to metabolic 
interactions. Levocetirizine at concentrations well above C<span class="Sub">max</span> level achieved within the therapeutic dose ranges is not an 
inhibitor of CYP isoenzymes 1A2, 2C9, 2C19, 2A1, 2D6, 2E1, and 3A4, and is not 
an inducer of UGT1A or CYP isoenzymes 1A2, 2C9 and 3A4.</p>
<p>No formal <span class="Italics">in vivo</span> drug interaction studies have 
been performed with levocetirizine. Studies have been performed with the racemic 
cetirizine [see <span class="Italics"><a href="#S7">Drug Interactions 
(7)</a></span>].</p>
<a href="http://"></a><a href="http://"></a><p><span class="Bold">    •    Pediatric Patients</span></p>
<p>Data from a pediatric pharmacokinetic study with oral administration of a 
single dose of 5 mg levocetirizine in 14 children age 6 to 11 years with body 
weight ranging between 20 and 40 kg show that C<span class="Sub">max</span> and 
AUC values are about 2-fold greater than that reported in healthy adult subjects 
in a cross-study comparison. The mean C<span class="Sub">max</span> was 450 ng/mL, 
occurring at a mean time of 1.2 hours, weight-normalized, total body clearance 
was 30% greater, and the elimination half-life 24% shorter in this pediatric 
population than in adults.</p>
<p>Dedicated pharmacokinetic studies have not been conducted in pediatric 
patients younger than 6 years of age. A retrospective population pharmacokinetic 
analysis was conducted in 324 subjects (181 children 1 to 5 years of age, 18 
children 6 to 11 years of age, and 124 adults 18 to 55 years of age) who 
received single or multiple doses of levocetirizine ranging from 1.25 mg to 30 
mg. Data generated from this analysis indicated that administration of 1.25 mg 
once daily to children 6 months to 5 years of age results in plasma 
concentrations similar to those of adults receiving 5 mg once daily.</p>
<a href="http://"></a><a href="http://"></a><p><span class="Bold">    •    Geriatric Patients</span></p>
<p>Limited pharmacokinetic data are available in elderly subjects. Following 
once daily repeat oral administration of 30 mg levocetirizine for 6 days in 9 
elderly subjects (65–74 years of age), the total body clearance was 
approximately 33% lower compared to that in younger adults. The disposition of 
racemic cetirizine has been shown to be dependent on renal function rather than 
on age. This finding would also be applicable for levocetirizine, as 
levocetirizine and cetirizine are both predominantly excreted in urine. 
Therefore, the XYZAL dose should be adjusted in accordance with renal function 
in elderly patients [see<span class="Italics"><a href="#S2"> Dosage and 
Administration (2)</a></span>].</p>
<a href="http://"></a><a href="http://"></a><p><span class="Bold">    •    Gender</span></p>
<p>Pharmacokinetic results for 77 patients (40 men, 37 women) were evaluated for 
potential effect of gender. The half-life was slightly shorter in women (7.08 ± 
1.72 hr) than in men (8.62 ± 1.84 hr); however, the body weight-adjusted oral 
clearance in women (0.67 ± 0.16 mL/min/kg) appears to be comparable to that in 
men (0.59 ± 0.12 mL/min/kg). The same daily doses and dosing intervals are 
applicable for men and women with normal renal function.</p>
<a href="http://"></a><a href="http://"></a><p><span class="Bold">    •    Race</span></p>
<p>The effect of race on levocetirizine has not been studied. As levocetirizine 
is primarily renally excreted, and there are no important racial differences in 
creatinine clearance, pharmacokinetic characteristics of levocetirizine are not 
expected to be different across races. No race-related differences in the 
kinetics of racemic cetirizine have been observed.</p>
<a href="http://"></a><a href="http://"></a><p><span class="Bold">    •    <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span></p>
<p>Levocetirizine exposure <span class="Bold">(</span>AUC<span class="Bold">) 
</span>exhibited 1.8-, 3.2-, 4.3-, and 5.7-fold increase in mild, moderate, 
severe, renal impaired, and end-stage <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> patients, respectively, 
compared to healthy subjects. The corresponding increases of half-life estimates 
were 1.4-, 2.0-, 2.9-, and 4-fold, respectively.</p>
<p>The total body clearance of levocetirizine after oral dosing was correlated 
to the creatinine clearance and was progressively reduced based on severity of 
<span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. Therefore, it is recommended to adjust the dose and dosing 
intervals of levocetirizine based on creatinine clearance in patients with mild, 
moderate, or severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. In end-stage <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> patients 
(CL<span class="Sub">CR</span> less than 10 mL/min) levocetirizine is contraindicated. 
The amount of levocetirizine removed during a standard 4‑hour hemodialysis 
procedure was less than 10%.</p>
<p>The dosage of XYZAL should be reduced in patients with mild <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. 
Both the dosage and frequency of administration should be reduced in patients 
with moderate or severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> [see <span class="Italics"><a href="#S2.4">Dosage and Administration (2.4)</a></span>].</p>
<a href="http://"></a><a href="http://"></a><p><span class="Bold">    •    <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></span></p>
<p>XYZAL has not been studied in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. The non-renal 
clearance (indicative of hepatic contribution) was found to constitute about 28% 
of the total body clearance in healthy adult subjects after oral 
administration.</p>
<p>As levocetirizine is mainly excreted unchanged by the kidney, it is unlikely 
that the clearance of levocetirizine is significantly decreased in patients with 
solely <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> [see <span class="Italics"><a href="#S2">Dosage and 
Administration (2)</a></span>].</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<p class="First">Enter section text here</p>
<div class="Section" data-sectionCode="34083-6">
<a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">No carcinogenicity studies have been performed with 
levocetirizine. However, evaluation of cetirizine carcinogenicity studies are 
relevant for determination of the carcinogenic potential of levocetirizine. In a 
2-year carcinogenicity study, in rats, cetirizine was not carcinogenic at 
dietary doses up to 20 mg/kg (approximately 15 times the maximum recommended 
daily oral dose in adults, approximately 10 times the maximum recommended daily 
oral dose in children 6 to 11 years of age and approximately 15 times the 
maximum recommended daily oral dose in children 6 months to 5 years of age on a 
mg/m<span class="Sup">2</span> basis). In a 2-year carcinogenicity study in mice, 
cetirizine caused an increased incidence of benign hepatic tumors in males at a 
dietary dose of 16 mg/kg (approximately 6 times the maximum recommended daily 
oral dose in adults, approximately 4 times the maximum recommended daily oral 
dose in children 6 to 11 years of age, and approximately 6 times the maximum 
recommended daily oral dose in children 6 months to 5 years of age on a 
mg/m<span class="Sup">2</span> basis). No increased incidence of benign tumors was 
observed at a dietary dose of 4 mg/kg (approximately 2 times the maximum 
recommended daily oral dose in adults, equivalent to the maximum recommended 
daily oral dose in children 6 to 11 years of age and approximately 2 times the 
maximum recommended daily oral dose in children 6 months to 5 years of age on a 
mg/m<span class="Sup">2</span> basis). The clinical significance of these findings 
during long-term use of XYZAL is not known.</p>
<p>Levocetirizine was not mutagenic in the Ames test, and not clastogenic in the 
human lymphocyte assay, the mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> assay, and <span class="Italics">in 
vivo </span>micronucleus test in mice.</p>
<p>In a fertility and general reproductive performance study in mice, cetirizine 
did not impair fertility at an oral dose of 64 mg/kg (approximately 25 times the 
recommended daily oral dose in adults on a mg/m<span class="Sup">2</span> basis).</p>
</div>
<div class="Section" data-sectionCode="34091-9">
<a name="section-12.2"></a><p></p>
<h2>13.2 Animal Toxicology</h2>
<p class="First">Reproductive Toxicology Studies</p>
<p>In rats and rabbits, levocetirizine was not teratogenic at oral doses up to 
200 and 120 mg/kg, respectively, (approximately 320 and 390, respectively, times 
the maximum recommended daily oral dose in adults on a mg/m<span class="Sup">2 
</span>basis).</p>
<p>In mice, cetirizine caused retarded pup <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> during lactation at an 
oral dose in dams of 96 mg/kg (approximately 40 times the maximum recommended 
daily oral dose in adults on a mg/m<span class="Sup">2</span> basis).</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<p class="First">Enter section text here</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.1"></a><p></p>
<h2>14.1 Seasonal and <span class="product-label-link" type="condition" conceptid="40486433" conceptname="Perennial allergic rhinitis">Perennial Allergic Rhinitis</span></h2>
<p class="First"><span>Adults and Adolescents 12 Years of Age 
and Older</span></p>
<p>The efficacy of XYZAL was evaluated in six randomized, placebo-controlled, 
double-blind clinical trials in adult and adolescent patients 12 years and older 
with symptoms of <span class="product-label-link" type="condition" conceptid="4280726" conceptname="Seasonal allergic rhinitis">seasonal allergic rhinitis</span> or <span class="product-label-link" type="condition" conceptid="40486433" conceptname="Perennial allergic rhinitis">perennial allergic rhinitis</span>. The 
six clinical trials include three dose-ranging trials of 2 to 4 weeks duration, 
one 2-week efficacy trial in patients with <span class="product-label-link" type="condition" conceptid="4280726" conceptname="Seasonal allergic rhinitis">seasonal allergic rhinitis</span>, and two 
efficacy trials (one 6-week and one 6-month) in patients with perennial allergic 
<span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span>.</p>
<p>These trials included a total of 2412 patients (1068 males and 1344 females) 
of whom 265 were adolescents 12 to 17 years of age. Efficacy was assessed using 
a total symptom score from patient recording of 4 symptoms (<span class="product-label-link" type="condition" conceptid="4328356" conceptname="Sneezing">sneezing</span>, 
<span class="product-label-link" type="condition" conceptid="4170297" conceptname="Sniffles">rhinorrhea</span>, nasal <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, and ocular <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>) in five studies and 5 symptoms 
(<span class="product-label-link" type="condition" conceptid="4328356" conceptname="Sneezing">sneezing</span>, <span class="product-label-link" type="condition" conceptid="4170297" conceptname="Sniffles">rhinorrhea</span>, nasal <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, ocular <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, and <span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">nasal congestion</span>) in 
one study. Patients recorded symptoms using a 0-3 categorical severity scale (0 
= absent, 1 = mild, 2 = moderate, 3 = severe) once daily in the evening 
reflective of the 24 hour treatment period. In one study, patients also recorded 
these symptoms in an instantaneous (1 hour before the next dose) manner. The 
primary endpoint was the mean total symptom score averaged over the first week 
and over 2 weeks for <span class="product-label-link" type="condition" conceptid="4280726" conceptname="Seasonal allergic rhinitis">seasonal allergic rhinitis</span> trials, and 4 weeks for 
<span class="product-label-link" type="condition" conceptid="40486433" conceptname="Perennial allergic rhinitis">perennial allergic rhinitis</span> trials.</p>
<p>The three dose-ranging trials were conducted to evaluate the efficacy of 
XYZAL 2.5, 5, and 10 mg once daily in the evening. One trial was 2 weeks in 
duration conducted in patients with <span class="product-label-link" type="condition" conceptid="4280726" conceptname="Seasonal allergic rhinitis">seasonal allergic rhinitis</span>, and two trials 
were 4 weeks in duration conducted in patients with <span class="product-label-link" type="condition" conceptid="40486433" conceptname="Perennial allergic rhinitis">perennial allergic rhinitis</span>. 
In these trials, each of the three doses of XYZAL demonstrated greater decrease 
in the reflective total symptom score than placebo and the difference was 
statistically significant for all three doses in two of the studies. Results for 
two of these trials are shown in Table 4.</p>
<a name="i0fadd284-9254-44ce-8ac3-89de56192a91"></a><table width="100%">
<caption><span>Table 4 Mean Reflective Total Symptom Score* in <span class="product-label-link" type="condition" conceptid="257007" conceptname="Allergic rhinitis">Allergic Rhinitis</span> Dose-Ranging Trials</span></caption>
<tbody class="Headless">
<tr class="First">
<td>
<span class="Bold">Treatment</span><br>
</td>
<td>
<span class="Bold">N</span><br>
</td>
<td>
<span class="Bold">Baseline</span><br>
</td>
<td><span class="Bold">On Treatment<br>Adjusted Mean<br></span></td>
<td>
<span class="Bold">Difference </span><br><span class="Bold"></span><span class="Bold">Estimate</span><br>
</td>
<td>
<span class="Bold">from Placebo</span><br><span class="Bold">95% CI</span><br>
</td>
<td>
<span class="Bold"><br>p-value</span><br>
</td>
</tr>
<tr>
<td><span class="Bold"><span class="product-label-link" type="condition" conceptid="4280726" conceptname="Seasonal allergic rhinitis">Seasonal Allergic Rhinitis</span></span></td>
<td><span class="Bold">Trial</span></td>
<td><span class="Bold">– Reflective total symptom score</span></td>
<td>
<span class="Bold"></span><br>
</td>
<td><br></td>
<td><br></td>
<td><br></td>
</tr>
<tr>
<td>XYZAL 2.5 mg<br>
</td>
<td>116<br>
</td>
<td>7.83<br>
</td>
<td>4.27<br>
</td>
<td>0.91<br>
</td>
<td>(0.37, 1.45)<br>
</td>
<td>0.001<br>
</td>
</tr>
<tr>
<td>XYZAL 5 mg<br>
</td>
<td>115<br>
</td>
<td>7.45<br>
</td>
<td>4.06<br>
</td>
<td>1.11<br>
</td>
<td>(0.57, 1.65)<br>
</td>
<td>less than 0.001<br>
</td>
</tr>
<tr>
<td>XYZAL 10 mg<br>
</td>
<td>118<br>
</td>
<td>7.15<br>
</td>
<td>3.57<br>
</td>
<td>1.61<br>
</td>
<td>(1.07, 21.5)<br>
</td>
<td>less than 0.001</td>
</tr>
<tr>
<td>Placebo<br>
</td>
<td>118<br>
</td>
<td>7.94<br>
</td>
<td>5.17<br>
</td>
<td><br></td>
<td><br></td>
<td><br></td>
</tr>
<tr>
<td><span class="Bold"><span class="product-label-link" type="condition" conceptid="40486433" conceptname="Perennial allergic rhinitis">Perennial Allergic Rhinitis</span></span></td>
<td><span class="Bold">Trial</span></td>
<td><span class="Bold">– Reflective total symptom score</span></td>
<td><br></td>
<td><br></td>
<td><br></td>
<td><br></td>
</tr>
<tr>
<td>XYZAL 2.5 mg<br>
</td>
<td>133<br>
</td>
<td>7.14<br>
</td>
<td>4.12<br>
</td>
<td>1.17<br>
</td>
<td>(0.71, 1.63)<br>
</td>
<td>less than 0.001</td>
</tr>
<tr>
<td>XYZAL 5 mg<br>
</td>
<td>127<br>
</td>
<td>7.18<br>
</td>
<td>4.07<br>
</td>
<td>1.22<br>
</td>
<td>(0.76, 1.69)<br>
</td>
<td>less than 0.001</td>
</tr>
<tr>
<td>XYZAL 10 mg<br>
</td>
<td>129<br>
</td>
<td>7.58<br>
</td>
<td>4.19<br>
</td>
<td>1.10<br>
</td>
<td>(0.64, 1.57)<br>
</td>
<td>less than 0.001</td>
</tr>
<tr class="Last">
<td>Placebo<br>
</td>
<td>128<br>
</td>
<td>7.22<br>
</td>
<td>5.29<br>
</td>
<td><br></td>
<td><br></td>
<td><br></td>
</tr>
</tbody>
</table>
<span class="Bold"></span>*   <br>Total symptom score is the sum of individual symptoms of <span class="product-label-link" type="condition" conceptid="4328356" conceptname="Sneezing">sneezing</span>, 
<span class="product-label-link" type="condition" conceptid="4170297" conceptname="Sniffles">rhinorrhea</span>, nasal <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, and ocular <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span> as assessed by patients on a 0-3 
categorical severity scale.<br><p>One clinical trial was designed to evaluate the efficacy of XYZAL 5 mg once 
daily in the evening compared with placebo in patients with seasonal allergic 
<span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span> over a 2-week treatment period. In this trial, XYZAL 5 mg demonstrated 
a greater decrease from baseline in the reflective and instantaneous total 
symptom score than placebo, and the difference was statistically significant 
(see <a href="#table5">Table 5</a>). The results of the instantaneous total 
symptom score support efficacy at the end of the dosing interval.</p>
<p>One clinical trial evaluated the efficacy of XYZAL 5 mg once daily in the 
evening compared to placebo in patients with <span class="product-label-link" type="condition" conceptid="40486433" conceptname="Perennial allergic rhinitis">perennial allergic rhinitis</span> over a 
6-week treatment period. Another trial conducted over a 6-month treatment period 
assessed efficacy at 4 weeks. XYZAL 5 mg demonstrated a greater decrease from 
baseline in the reflective total symptom score than placebo and the difference 
from placebo was statistically significant. Results of one of these trials are 
shown in Table 5.</p>
<a name="if2669bd0-ff1c-437a-8b37-f6adfefaaf3b"></a><table width="100%">
<caption><span>Table 5 Mean Reflective Total Symptom Score* and Instantaneous Total Symptom Score in <span class="product-label-link" type="condition" conceptid="257007" conceptname="Allergic rhinitis">Allergic Rhinitis</span> Trials</span></caption>
<tbody class="Headless">
<tr class="First">
<td>
<span class="Bold">Treatment</span><br>
</td>
<td>
<span class="Bold">N</span><br>
</td>
<td>
<span class="Bold">Baseline</span><br>
</td>
<td><span class="Bold">On Treatment<br>Adjusted Mean<br></span></td>
<td>
<span class="Bold">Difference </span><br><span class="Bold"></span><span class="Bold">Estimate</span>
</td>
<td>
<span class="Bold">from Placebo</span><br><span class="Bold">95% CI</span>
</td>
<td>
<br><span class="Bold">p-value</span><br>
</td>
</tr>
<tr>
<td><span class="Bold"><span class="product-label-link" type="condition" conceptid="4280726" conceptname="Seasonal allergic rhinitis">Seasonal Allergic Rhinitis</span></span></td>
<td><span class="Bold">Trial</span></td>
<td><span class="Bold">– Reflective total symptom score</span></td>
<td><br></td>
<td><br></td>
<td><br></td>
<td><br></td>
</tr>
<tr>
<td>XYZAL 5 mg<br>
</td>
<td>118<br>
</td>
<td>8.40<br>
</td>
<td>5.20<br>
</td>
<td>.089<br>
</td>
<td>(0.30, 1.47)<br>
</td>
<td>0.003<br>
</td>
</tr>
<tr>
<td>Placebo<br>
</td>
<td>117<br>
</td>
<td>8.50<br>
</td>
<td>6.09<br>
</td>
<td><br></td>
<td><br></td>
<td><br></td>
</tr>
<tr>
<td><span class="Bold"><span class="product-label-link" type="condition" conceptid="4280726" conceptname="Seasonal allergic rhinitis">Seasonal Allergic Rhinitis</span></span></td>
<td><span class="Bold">Trial</span></td>
<td><span class="Bold">– Instantaneous total symptom score</span></td>
<td><br></td>
<td><br></td>
<td><br></td>
<td><br></td>
</tr>
<tr>
<td>XYZAL 5 mg<br>
</td>
<td>118<br>
</td>
<td>7.24<br>
</td>
<td>4.58<br>
</td>
<td>0.73<br>
</td>
<td>(0.17, 1.28)<br>
</td>
<td>0.011<br>
</td>
</tr>
<tr>
<td>Placebo<br>
</td>
<td>117<br>
</td>
<td>7.48<br>
</td>
<td>5.30<br>
</td>
<td><br></td>
<td><br></td>
<td><br></td>
</tr>
<tr>
<td><span class="Bold"><span class="product-label-link" type="condition" conceptid="40486433" conceptname="Perennial allergic rhinitis">Perennial Allergic Rhinitis</span></span></td>
<td><span class="Bold">Trial</span></td>
<td><span class="Bold">– Reflective total symptom score</span></td>
<td><br></td>
<td><br></td>
<td><br></td>
<td><br></td>
</tr>
<tr>
<td>XYZAL 5 mg<br>
</td>
<td>150<br>
</td>
<td>7.69<br>
</td>
<td>3.93<br>
</td>
<td>1.17<br>
</td>
<td>(0.70, 1.64)<br>
</td>
<td>less than 0.001<br>
</td>
</tr>
<tr class="Last">
<td>Placebo<br>
</td>
<td>142<br>
</td>
<td>7.44<br>
</td>
<td>5.10<br>
</td>
<td><br></td>
<td><br></td>
<td><br></td>
</tr>
</tbody>
</table>*   <br>Total symptom score is the sum of individual symptoms of <span class="product-label-link" type="condition" conceptid="4328356" conceptname="Sneezing">sneezing</span>, 
<span class="product-label-link" type="condition" conceptid="4170297" conceptname="Sniffles">rhinorrhea</span>, nasal <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, and ocular <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span> as assessed by patients on a 0-3 
categorical severity scale.<br><p>Onset of action was evaluated in two environmental exposure unit studies in 
<span class="product-label-link" type="condition" conceptid="257007" conceptname="Allergic rhinitis">allergic rhinitis</span> patients with a single dose of XYZAL 2.5 or 5 mg. XYZAL 5 mg 
was found to have an onset of action 1 hour after oral intake. Onset of action 
was also assessed from the daily recording of symptoms in the evening before 
dosing in the seasonal and <span class="product-label-link" type="condition" conceptid="40486433" conceptname="Perennial allergic rhinitis">perennial allergic rhinitis</span> trials. In these trials, 
onset of effect was seen after 1 day of dosing.</p>
<a href="http://"></a><a href="http://"></a><p><span>Pediatric Patients Less than 12 Years of 
Age</span></p>
<p>There are no clinical efficacy trials with XYZAL 2.5 mg once daily in 
pediatric patients under 12 years of age, and no clinical efficacy trials with 
XYZAL 1.25 mg once daily in pediatric patients 6 months to 5 years of age. The 
clinical efficacy of XYZAL in pediatric patients under 12 years of age has been 
extrapolated from adult clinical efficacy trials based on pharmacokinetic 
comparisons [see<span class="Italics"><a href="#S8.4">Use in Specific Populations 
(8.4)</a></span>].</p>
<br><br>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.2"></a><p></p>
<h2>14.2 Chronic <span class="product-label-link" type="condition" conceptid="140803" conceptname="Idiopathic urticaria">Idiopathic Urticaria</span></h2>
<p class="First"><span>Adult Patients 18 Years of Age and 
Older</span></p>
<p>The efficacy of XYZAL for the treatment of the uncomplicated skin 
manifestations of chronic <span class="product-label-link" type="condition" conceptid="140803" conceptname="Idiopathic urticaria">idiopathic urticaria</span> was evaluated in two 
multi-center, randomized, placebo-controlled, double-blind clinical trials of 4 
weeks duration in adult patients 18 to 85 years of age with chronic idiopathic 
<span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>. The two trials included one 4-week dose-ranging trial and one 4-week 
single-dose level efficacy trial. These trials included 423 patients (139 males 
and 284 females). Most patients (greater than 90%) were Caucasian and the mean age was 
41. Of these patients, 146 received XYZAL 5 mg once daily in the evening. 
Efficacy was assessed based on patient recording of <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span> severity on a 
severity score of 0–3 (0 = none to 3 = severe). The primary efficacy endpoint 
was the mean reflective <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span> severity score over the first week and over the 
entire treatment period. Additional efficacy variables were the instantaneous 
<span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span> severity score, the number and size of <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">wheals</span>, and duration of 
<span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>.</p>
<p>The dose-ranging trial was conducted to evaluate the efficacy of XYZAL 2.5, 
5, and 10 mg once daily in the evening. In this trial, each of the three doses 
of XYZAL demonstrated greater decrease in the reflective <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span> severity score 
than placebo and the difference was statistically significant for all three 
doses (see <a href="#section-">  Table 6</a>).</p>
<p>The single dose level trial evaluated the efficacy of XYZAL 5 mg once daily 
in the evening compared to placebo in patients with chronic <span class="product-label-link" type="condition" conceptid="140803" conceptname="Idiopathic urticaria">idiopathic urticaria</span> 
over a 4-week treatment period. XYZAL 5 mg demonstrated a greater decrease from 
baseline in the reflective <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span> severity score than placebo and the 
difference from placebo was statistically significant.</p>
<p>Duration of <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, number and size of <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">wheals</span>, and instantaneous <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span> 
severity score also showed significant improvement over placebo. The significant 
improvement in the instantaneous <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span> severity score over placebo confirmed 
end of dosing interval efficacy (see <a href="#section-">  Table 6</a>).</p>
<a name="ie11c29e0-5e28-45d9-8abd-9cf4239d1a8d"></a><table width="100%">
<caption><span>Table 6 Mean Reflective <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span> Severity Score in Chronic <span class="product-label-link" type="condition" conceptid="140803" conceptname="Idiopathic urticaria">Idiopathic Urticaria</span> Trials</span></caption>
<tbody class="Headless">
<tr class="First">
<td>
<span class="Bold">Treatment</span><br>
</td>
<td>
<span class="Bold">N</span><br>
</td>
<td>
<span class="Bold">Baseline</span><br>
</td>
<td><span class="Bold">On Treatment<br>Adjusted Mean<br></span></td>
<td>
<span class="Bold">Difference</span><br><span class="Bold"></span><span class="Bold">Estimate</span><br><span class="Bold"></span>
</td>
<td>
<span class="Bold">from Placebo</span><br><span class="Bold"><span class="Bold">95% CI</span></span><br><span class="Bold"></span><span class="Bold"><span class="Bold"></span></span>
</td>
<td>
<span class="Bold"><br></span><span class="Bold">p-value</span><br><span class="Bold"></span>
</td>
</tr>
<tr>
<td><span class="Bold">Dose-Ranging</span></td>
<td>
<span class="Bold">Trial</span><br>
</td>
<td>
<span class="Bold">- Reflective <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span> severity score</span><br>
</td>
<td><br></td>
<td><br></td>
<td><br></td>
<td><br></td>
</tr>
<tr>
<td>XYZAL 2.5 mg<br>
</td>
<td>69<br>
</td>
<td>2.08<br>
</td>
<td>1.02<br>
</td>
<td>0.82<br>
</td>
<td>(0.58, 1.06)<br>
</td>
<td>less than 0.001<br>
</td>
</tr>
<tr>
<td>XYZAL 5 mg<br>
</td>
<td>62 <br>
</td>
<td>2.07<br>
</td>
<td>0.92<br>
</td>
<td>0.91<br>
</td>
<td>(0.66, 1.16)<br>
</td>
<td>less than 0.001<br>
</td>
</tr>
<tr>
<td>XYZAL 10 mg<br>
</td>
<td>55<br>
</td>
<td>2.04<br>
</td>
<td>0.73<br>
</td>
<td>1.11<br>
</td>
<td>(0.85, 1.37)<br>
</td>
<td>less than 0.001<br>
</td>
</tr>
<tr>
<td>Placebo<br>
</td>
<td>60<br>
</td>
<td>2.25<br>
</td>
<td>1.84<br>
</td>
<td><br></td>
<td><br></td>
<td><br></td>
</tr>
<tr>
<td>
<span class="Bold">Chronic <span class="product-label-link" type="condition" conceptid="140803" conceptname="Idiopathic urticaria">Idiopathic Urticaria</span></span><br>
</td>
<td><span class="Bold">Trial</span></td>
<td>
<span class="Bold">- Reflective <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span> severity score</span><br>
</td>
<td><br></td>
<td><br></td>
<td><br></td>
<td><br></td>
</tr>
<tr>
<td>XYZAL 5 mg<br>
</td>
<td>80<br>
</td>
<td>2.07<br>
</td>
<td>0.94<br>
</td>
<td>0.62<br>
</td>
<td> (0.38, 0.86)<br>
</td>
<td>less than 0.001<br>
</td>
</tr>
<tr class="Last">
<td>Placebo<br>
</td>
<td>82<br>
</td>
<td>2.06<br>
</td>
<td>1.56<br>
</td>
<td><br></td>
<td><br></td>
<td><br></td>
</tr>
</tbody>
</table>
<br><a href="#section-"></a><a href="#section-"></a><p><span>Pediatric Patients</span></p>
<p>There are no clinical efficacy trials in pediatric patients with chronic 
<span class="product-label-link" type="condition" conceptid="140803" conceptname="Idiopathic urticaria">idiopathic urticaria</span> [see <span class="Italics"><a href="#section-">  Use in Specific 
Populations (8.4)</a></span>].</p>
<p></p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">XYZAL tablets are white, film-coated, oval-shaped, scored, 
imprinted (with the letter Y in red color on both halves of the scored tablet) 
and contain 5 mg levocetirizine dihydrochloride. They are supplied in bottles of:<br></p>
<p>30 Tablets  <span class="Bold">NDC 54868-5829-0<br></span></p>
<p><br></p>
<p>XYZAL oral solution is a clear, colorless liquid containing 0.5 mg of 
levocetirizine dihydrochloride per mL.</p>
<p>Oral solution in 5 oz glass bottles  <span class="Bold">NDC 54868-6115-0<br></span></p>
<a href="http://"></a><a href="http://"></a><p><span class="Bold"><br></span></p>
<p><span class="Bold">Storage:</span></p>
<p>Store at 20-25°C (68-77°F); excursions permitted to 15‑30°C (59-86°F) [see 
USP Controlled Room Temperature].</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First">Enter section text here</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-15.1"></a><p></p>
<h2>17.1 Activities Requiring Mental Alertness</h2>
<p class="First">Patients should be cautioned against engaging in hazardous occupations requiring 
complete mental alertness, and motor coordination such as operating machinery or 
driving a motor vehicle after ingestion of XYZAL.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-15.2"></a><p></p>
<h2>17.2 Concomitant Use of Alcohol and other Central Nervous System Depressants</h2>
<p class="First">Concurrent use of XYZAL with alcohol or other central nervous system depressants 
should be avoided because additional reduction in mental alertness may occur.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-15.3"></a><p></p>
<h2>17.3 Dosing of XYZAL</h2>
<p class="First">The daily dose in adults and adolescents 12 years of age and older should not 
exceed 5 mg once daily in the evening. In children 6 to 11 years of age the 
recommended dose is 2.5 mg once daily in the evening. Patients should be advised 
to not ingest more than the recommended dose of XYZAL because of the increased 
risk of <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> at higher doses.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-16"></a><p></p>
<p class="First">Manufactured by</p>
<p>UCB Farchim SA</p>
<p>CH-1630 Bulle<br>(Switzerland)<br>For UCB Inc.<br>Smyrna,GA 30080 (USA)</p>
<p>XYZAL is a registered trademark of the UCB Group of companies.</p>
<p>©2008 UCB, Inc. All rights reserved.</p>
<br><p><br></p>
<p>Repackaging and/or Relabeling of "Additional Barcode" by:<br>Physicians Total Care, Inc.<br>Tulsa, OK    74146<br></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-17"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL</h1>
<p class="First"><span class="Bold">Xyzal<span class="Sup">®</span><br></span>(Levocetirizine 
Dihydrochloride)<br>5 mg tablet<br>Rx only</p>
<div class="Figure"><img alt="image of tablet package label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=371ca86d-7ffd-4f20-b6c6-af0a9ff7362f&amp;name=package%20label%2001.jpg"></div>
<br><p><br></p>
<p><span class="Bold">Xyzal<span class="Sup">®</span><br></span>(Levocetirizine 
Dihydrochloride)<br>5 mL oral solution<br>Rx only</p>
<p><img alt="image of solution package label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=371ca86d-7ffd-4f20-b6c6-af0a9ff7362f&amp;name=package%20label%2002.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>XYZAL 		
					</strong><br><span class="contentTableReg">levocetirizine dihydrochloride tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-5829(NDC:0024-5800)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>LEVOCETIRIZINE DIHYDROCHLORIDE</strong> (LEVOCETIRIZINE) </td>
<td class="formItem">LEVOCETIRIZINE DIHYDROCHLORIDE</td>
<td class="formItem">5 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">white</td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL</td>
<td class="formLabel">Size</td>
<td class="formItem">8mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">Y</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-5829-0</td>
<td class="formItem">30  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022064</td>
<td class="formItem">11/06/2007</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>XYZAL 		
					</strong><br><span class="contentTableReg">levocetirizine dihydrochloride solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-6115(NDC:0024-5801)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>LEVOCETIRIZINE DIHYDROCHLORIDE</strong> (LEVOCETIRIZINE) </td>
<td class="formItem">LEVOCETIRIZINE DIHYDROCHLORIDE</td>
<td class="formItem">0.5 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM ACETATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ACETIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>GLYCERIN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>METHYLPARABEN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>PROPYLPARABEN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SACCHARIN SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-6115-0</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">148 mL in 1 BOTTLE, GLASS</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022157</td>
<td class="formItem">04/27/2010</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Physicians Total Care, Inc.
							(194123980)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Physicians Total Care, Inc.</td>
<td class="formItem"></td>
<td class="formItem">194123980</td>
<td class="formItem">repack, relabel</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 5/2010<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>8b3759e9-e20f-433d-acdb-173863e2b2ae</div>
<div>Set id: 371ca86d-7ffd-4f20-b6c6-af0a9ff7362f</div>
<div>Version: 1</div>
<div>Effective Time: 20100511</div>
</div>
</div> <div class="DistributorName">Physicians Total Care, Inc.</div></p>
</body></html>
